Compare LTBR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTBR | KALV |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 575.6M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | LTBR | KALV |
|---|---|---|
| Price | $14.99 | $16.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 02-25-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.10 | $8.67 |
| 52 Week High | $31.34 | $19.00 |
| Indicator | LTBR | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 54.89 |
| Support Level | $15.84 | $15.22 |
| Resistance Level | $18.12 | $16.16 |
| Average True Range (ATR) | 1.49 | 0.88 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 8.24 | 76.95 |
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.